Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in a Phase II study, researchers ...
Oct 26, 2022
0
55
A study led by an Oregon State University pharmaceutical sciences researcher has produced a proof of principle for a new "universal" means of treating COVID-19.
Oct 18, 2022
0
38
By analyzing key enzymes in a new way, an international team led by researchers at Weill Cornell Medicine has discovered how a well-known signaling molecule can either stimulate or suppress tumor growth depending on where ...
Oct 6, 2022
0
41
A new study from the Garvan Institute of Medical Research shows how rises in core body temperature may trigger the inflammatory flares in people with a rare genetic autoinflammatory disease.
Oct 3, 2022
0
808
The advent of small-molecule targeted therapies, a decade ago, revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite a remarkable ...
Sep 22, 2022
0
31
A team of scientists led by Duke-NUS Medical School have identified an important pathway that gets disrupted in the advanced form of non-alcoholic fatty liver disease known as non-alcoholic steatohepatitis (NASH)—and intervening ...
Sep 21, 2022
0
48
Researchers have found the first experimental evidence explaining why the COVID-19 virus produces variants, such as delta and omicron, so quickly.
Sep 14, 2022
0
80
Cancer cells often grow in environments that are low in nutrients, and they cope with this challenge by switching their metabolism to using proteins as alternative "food". Building on genetic screens, an international team ...
Sep 9, 2022
0
90
One of the most upsetting aspects of age-related memory decline is not being able to remember the face that accompanies the name of a person you just talked with hours earlier. While researchers don't understand why this ...
Sep 8, 2022
0
125
The U.S. Food and Drug Administration has approved Xenpozyme (olipudase alfa) for pediatric and adult patients with acid sphingomyelinase deficiency (ASMD), a rare genetic disease.
Sep 5, 2022
0
18
